Patient Support Hotline

Call (844) 244-1309

ZERO360 is a free, comprehensive patient support service to help patients and their families navigate insurance and financial obstacles to cover treatment and other critical needs associated with cancer.


Subscribe to our E-Newsletter

Stay up-to-date on the latest news about prostate cancer. Join our distribution list to receive periodic email updates and our monthly e-newsletter.

  • Patient Support (844) 244-1309
  • Search
  • e-News Signup Enews Signup
  • Run/Walk
  • Donate

- test

Genomic Test Does Not Increase Active Surveillance Acceptance for Treating Favorable-Risk Prostate Cancer

The results from a trial evaluating the Genomic Prostate Score did not find an increase in active surveillance acceptance amongst... Read More

Focal Ablation Technique for Intermediate-Risk Prostate Cancer Continues to Show Safety

The NanoTherm therapy system for focal ablation of intermediate-risk prostate cancer continued to show a tolerable safety profile in a... Read More

Treatment Targeting Is Key to Success in Oncology

With precision-guided approaches to care establishing themselves across tumor types, newer systemic therapy regimens are almost exclusively developed for the... Read More

Black Men with Prostate Cancer Treated with Radiation in VA Health System See Improved Outcomes

Black race was associated with improved prostate cancer-specific mortality and all-cause mortality among men with nonmetastatic prostate cancer who received... Read More

Men With Advanced Prostate Cancer, Be Informed About Your Genetics!

In this video, Dr. Heather Cheng briefly outlines the GENTleMEN study of the impact of genetic testing for men with advanced... Read More

Adjuvant Docetaxel Fails in Higher-Risk Prostate Cancer

Adjuvant docetaxel without prednisone failed to improve biochemical disease-free survival in men with intermediate- or high-risk prostate cancer who have... Read More

Smoking at Time of Treatment Worsens Prostate Cancer Outcomes

Current smokers at the time of primary treatment for localized prostate cancer have a higher risk of negative outcomes, including... Read More

Abiraterone May Be More Effective in Black Men With Prostate Cancer

Black men with metastatic castration-resistant prostate cancer (CRPC) who received hormonal therapy with the adrenal inhibitor abiraterone had greater and... Read More

Initiation of ADT in a Man With Locally Advanced Prostate Cancer and Multiple Cardiovascular Risk Factors

The case: A 65-year-old man presented with locally advanced, high-risk prostate cancer. He shad type 2 diabetes, he was also overweight... Read More

Whole-Genome Analyses Expand Genetic Picture of Prostate Cancer

Researchers have found a number of previously unidentified genes that may act as drivers of prostate cancer. A new study... Read More

1 2 3 4